(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

BROMAC

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: WordOffice: United States

Quick snapshot

BROMAC

ST13

US500000090191359

Class

5

Filing

90191359

Registration

6617801

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

25

Latest update

01/03/2023

Trademark type

Word

Nice classes

5

Filing date

09/18/2020

Registration date

01/18/2022

Expiration date

-

Complete case details

Structured fields from the responsible authority and the official record.

Status date

01/18/2022

Last transaction

01/18/2022

Responsible office

United States Patent and Trademark Office

Status code

700

Official register

Principal Register

Filing basis

Intent to use, Foreign priority

Drawing code

4

Owner type

16

Owner location

Malvern VIC, AU

Examiner

STEEL, ALYSSA PALADINO

Law office

N60

Current location

PUBLICATION AND ISSUE SECTION

Holders and representatives

Holders

Mucpharm Pty Ltd

Representatives

JOE MCKINNEY MUNCY MUNCY, GEISSLER, OLDS & LOWE, P.C.

Technical classification

Nice Classes

Class 5

Vienna Codes

No Vienna codes available.

Goods and services

Class 5

Anti-bacterial pharmaceuticals; anti-cancer drugs; anti-cancer pharmaceutical preparations; anti-fungal preparations; antiviral pharmaceutical preparations; bacteria removersantimicrobial preparations for inhibiting the growth of bacteria; biofilm removersantimicrobial preparations for inhibiting the growth of biofilms; biological preparations for the treatment of cancer and pseudomyxoma peritonei; chemical preparations containing enzymes for pharmaceutical purposesfor the prevention and treatment of cancer and pseudomyxoma peritoneifor inhibiting the growth of bacteria or biofilmsfor destroying biofilm infectionsfor treating cystic fibrosissputum retentionchest infectionsrespiratory conditionssevere asthmaCOPD (chronic obstructive pulmonary disease)ARDS (acute respiratory distress syndrome)pneumoniafungal infections and haemophilia; chemical preparations for pharmaceutical usefor the prevention and treatment of cancer and pseudomyxoma peritoneifor inhibiting the growth of bacteria or biofilmsfor destroying biofilm infectionsfor treating cystic fibrosissputum retentionchest infectionsrespiratory conditionssevere asthmaCOPDARDSpneumoniafungal infections and haemophilia; compounds being pharmaceutical preparations for treating cancer; pharmaceutical compositions for the treatment and prevention of cancer and pseudomyxoma peritoneifor inhibiting the growth of bacteria or biofilmsfor destroying biofilm infectionsfor treating cystic fibrosissputum retentionchest infectionsrespiratory conditionssevere asthmaCOPDARDSpneumoniafungal infections and haemophilia; pharmaceutical preparations for the treatment and prevention of cancer and pseudomyxoma peritoneifor inhibiting the growth of bacteria or biofilmsfor destroying biofilm infectionsfor treating cystic fibrosissputum retentionchest infectionsrespiratory conditionssevere asthmaCOPDARDSpneumoniafungal infections and haemophilia; pharmaceutical preparations for the treatment of cancer; pharmaceutical products for the prevention and treatment of pseudomyxoma peritonei; pharmaceutical preparations for use in combination therapy for the treatment of cancer and pseudomyxoma peritonei; pharmaceutical preparations for treating glue earcystic fibrosissputum retentionchest infectionsrespiratory conditionshaemophiliamyocardial infarctioncoronary artery diseasestrokemassive pulmonary embolismacute limb ischemiastent-related thrombosis or haemarthrosis; preparations of plantsplant extracts for pharmaceutical use

Publications

History of USPTO decisions and trademark events.

25 publications found

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

01/03/2023

ECDR

TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS

01/03/2023

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

01/03/2023

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

01/03/2023

R.PR

REGISTERED-PRINCIPAL REGISTER

01/18/2022

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

11/02/2021

PUBO

PUBLISHED FOR OPPOSITION

11/02/2021

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

10/13/2021

PREV

LAW OFFICE PUBLICATION REVIEW COMPLETED

09/28/2021

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

09/28/2021

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

09/27/2021

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

09/27/2021

ALIE

ASSIGNED TO LIE

09/26/2021

ERSI

TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED

09/20/2021

GNS3

NOTIFICATION OF LETTER OF SUSPENSION E-MAILED

07/29/2021

GNSL

LETTER OF SUSPENSION E-MAILED

07/29/2021

CNSL

SUSPENSION LETTER WRITTEN

07/29/2021

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

07/12/2021

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

07/12/2021

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

07/12/2021

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

02/03/2021

GNRT

NON-FINAL ACTION E-MAILED

02/03/2021

CNRT

NON-FINAL ACTION WRITTEN

02/03/2021

DOCK

ASSIGNED TO EXAMINER

02/03/2021

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

10/27/2020

Continuous trademark protection

Get notified about every new filing that threatens BROMAC or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.